9FJD | pdb_00009fjd

Expanded CVB1-VLP (Tween80)


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.15 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation   3D Report Full Report


This is version 2.0 of the entry. See complete history


Literature

Comparison of structure and immunogenicity of CVB1-VLP and inactivated CVB1 vaccine candidates.

Soppela, S.Plavec, Z.Grohn, S.Jartti, M.Oikarinen, S.Laajala, M.Marjomaki, V.Butcher, S.J.Hankaniemi, M.M.

(2024) Res Sq 

  • DOI: https://doi.org/10.21203/rs.3.rs-4545395/v1
  • Primary Citation of Related Structures:  
    9FJC, 9FJD, 9FJE

  • PubMed Abstract: 

    Coxsackievirus B1 (CVB1) is a common cause of acute and chronic myocarditis, dilated cardiomyopathy and aseptic meningitis. However, no CVB-vaccines are available for human use. In this study, we investigated the immunogenicity of virus-like particle (VLP) and inactivated whole-virus vaccines for CVB1 when administrated to mice via either subcutaneous or intranasal routes formulated with and without commercial and experimental adjuvants. Here, the potential of utilizing epigallocatechin-3-gallate (EGCG) as a mucosal adjuvant synergistically with its ability to inactivate the virus were investigated. EGCG had promising adjuvant properties for CVB1-VLP when administered via the parenteral route but limited efficacy via intranasal administration. However, intranasal administration of the formalin-inactivated virus induced high CVB1-specific humoral, cellular, and mucosal immune responses. Also, based on CVB1-specific IgG-antibody responses, we conclude that CVB1-VLP can be taken up by immune cells when administrated intranasally and further structural engineering for the VLP may increase the mucosal immunogenicity. The preparations contained mixtures of compact and expanded A particles with 85% expanded in the formalin-inactivated virus, but only 52% in the VLP observed by cryogenic electron microscopy. To correlate the structure to immunogenicity, we solved the structures of the CVB1-VLP and the formalin-inactivated CVB1 virus at resolutions ranging from 2.15 A to 4.1 A for the expanded and compact VLP and virus particles by image reconstruction. These structures can be used in designing mutations increasing the stability and immunogenicity of CVB1-VLP in the future. Overall, our results highlight the potential of using formalin inactivated CVB1 vaccine in mucosal immunization programs and provide important information for future development of VLP-based vaccines against all enteroviruses.


  • Organizational Affiliation
    • Tampere University.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Capsid protein VP1A [auth 1]220Coxsackievirus B1Mutation(s): 0 
UniProt
Find proteins for W8GTF7 (Coxsackievirus B1)
Explore W8GTF7 
Go to UniProtKB:  W8GTF7
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupW8GTF7
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChains Sequence LengthOrganismDetailsImage
Capsid protein VP2B [auth 2]249Coxsackievirus B1Mutation(s): 0 
UniProt
Find proteins for A0A2S0RQC2 (Coxsackievirus B1)
Explore A0A2S0RQC2 
Go to UniProtKB:  A0A2S0RQC2
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupA0A2S0RQC2
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 3
MoleculeChains Sequence LengthOrganismDetailsImage
Capsid protein VP3C [auth 3]232Coxsackievirus B1Mutation(s): 0 
UniProt
Find proteins for L7UV52 (Coxsackievirus B1)
Explore L7UV52 
Go to UniProtKB:  L7UV52
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupL7UV52
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.15 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Sigrid Juselius FoundationFinland95-7202-38
Sigrid Juselius FoundationFinland121-8570-56
Jane and Aatos Erkko FoundationFinland210034
Jane and Aatos Erkko FoundationFinland240002

Revision History  (Full details and data files)

  • Version 1.0: 2024-07-31
    Type: Initial release
  • Version 2.0: 2025-10-01
    Type: Coordinate replacement
    Reason: Sequence discrepancy
    Changes: Atomic model, Data collection, Database references, Derived calculations, Polymer sequence, Structure summary